Indivior PLC

Indivior Pharmaceuticals reported earnings per share of $0.98 for the quarter ended June 30, 2026, compared with $0.14 a year earlier. Revenue rose 13.58 percent to $343.0 million from $302.0 million in the year-ago period. The company presented the figures at a financial conference on August 3, 2026. » More on finanzen.net

Supernus Pharmaceuticals rose 20.7% in premarket trading to $53.88 after a definitive merger agreement with Indivior was announced as a stock swap. Supernus shareholders will receive 1.5401 Indivior common shares per Supernus share; Indivior shareholders will receive an aggregate special dividend of $1.0 billion before closing (financed by a $650 million term loan). The combined company will be named Supernus and will continue trading under the ticker SUPN; analysts view the deal as value-creating and had recently issued positive assessments and price targets. Supernus also reaffirmed its 2026 revenue guidance and reported strong revenue growth in the first quarter. » More on de.investing.com

Indivior’s shares rose about 4.6% after the company announced an accelerated $175 million share buyback. The agreement with Barclays is part of an existing $400 million buyback program; Indivior will pay $175 million upfront and expects the short-term delivery of 3,717,473 shares, with final settlement to occur by the end of June 2026. The company does not expect the buyback to affect its current financial guidance and reserves the right to deploy the remaining $100 million depending on market conditions. » More on de.investing.com